Press Room

DDF - Global Drug Delivery & Formulation Summit 2025

Start
Monday, June 02, 2025 - 09:00
End
Wednesday, June 04, 2025 - 18:00
Location: Berlin, Germany
Booth Number: Table #16
Synthetic Sugars | Hovione

Hovione is exhibiting at DDF Berlin, a leading 3-day summit on drug delivery, formulation and device development that attracts over 400 senior pharmaceutical leaders. At this event, top-notch experts engage in discussions on the latest advancements in the industry, presenting case studies and sharing invaluable experience.

 

Do not miss our Solution Spotlight Session, on June 2 (Room 4, 10:00 - 10:30 am):

“Next generation of Excipients for Proteins: enhancing stability and reducing viscosity”  

The pharmaceutical industry continues to push the boundaries of innovation, particularly in the field of biologics, which now represents a significant and growing segment of therapeutic development. As these complex molecules become more prevalent, addressing formulation challenges such as stability and high viscosity becomes increasingly critical. Traditional excipients often fall short in meeting the unique demands of modern biologics, prompting the need for next-generation solutions. 

Novel excipients offer a promising path forward, enabling enhanced protein stability, reduced viscosity, and improved manufacturability and delivery. With regulatory frameworks beginning to recognize the importance of excipient innovation, now is a pivotal moment for industry stakeholders to explore and implement these advancements in protein therapeutics development. 

In our Solution Spotlight Session, presented by Joana Cristovão – R&D Manager – we introduce a platform of novel synthetic sugars designed to ensure more robust biopharmaceuticals. Case studies demonstrate the significant improvements these sugars provide in enhancing model proteins manufacturing processes, stability, and viscosity reduction across various applications.

Session Highlights:

  • Tackling complexity in protein therapeutics: Addressing the limitations of traditional formulations for high-concentration and complex biologics.
  • Next-gen excipients in action: Real-world data showing improved stability and manufacturability using novel excipients.
     

Speak with our experts and learn how our extensive knowledge and experience can support your project from early stages of development to commercialization.

We look forward to seeing you at DDF Berlin.

Schedule a meeting today.

 

schedule a meeting

 

 

 

 

 

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025